Human pleasant touches promote feelings of security, supportiveness, and wellbeing. Conversely, human unpleasant touches promote the body for either “fight or flight” or “short term acute stress” during emergencies, feeling of stress or danger. The promoted stress response is released from the hypothalamus by the sympathetic nerve system further to the spinal cord to reach the signals to the adrenal medulla, where stress hormones adrenaline is released. Adrenaline, which is characterized by a mimic sympathetic nerve system, interacts with α and β receptors on different organs. The aim for this study was to investigate whether the stroker (partner/stranger) touch effects on adrenaline hormone releases. The null hypothesis for this study entails a significant adrenaline reduction in partners’ touches compared with strangers’ touches. Indirect competitive ELISA method was used, and concentration data of a total of sixteen participants was obtained. Whitney-U test was carried out to compare group differences within stroker (stranger/partner) touches and adrenaline releasing level. In addition, correlation in adrenaline with noradrenaline and oxytocin hormones was obtained using Spearman’s correlation test. The significant p-value 0.05 was conducted. The result of this study showed no differences between stroker (partner/stranger) associated with adrenaline hormone release. Correlation between partner maximum (max) concentration data for both oxytocin and adrenaline had significant differences. However, max variables for adrenaline and noradrenaline within stroker did not show significant differences. The conclusion of this study is that the gentle touch stimulus used in this study was not enough to detect stress hormone in adrenaline.

Subjects participating in magnetic resonance imaging (MRI) examinations regularly report anxiety and stress related reactions. This may result in impaired data quality and premature termination of scans. Moreover, cognitive functions and neural substrates can be altered by stress. While prior studies investigated pre–post scan differences in stress reactions only, the present study provides an in-depth analysis of mood changes and hormonal fluctuations during the time course of a typical fMRI session. Thirty-nine subjects participated in the study. Subjective mood, salivary alpha-amylase (sAA) and cortisol were assessed at six time points during the lab visit. Associations between hormonal data and neural correlates of a visual detection task were observed using a region of interest approach applied to the thalamic region. Mood and hormonal levels changed significantly during the experiment. Subjects were most nervous immediately after entering the scanner. SAA was significantly elevated after MRI preparation. A subgroup of n = 5 (12.8%) subjects showed pronounced cortisol responses exceeding 2.5 nmol/l. Preliminary fMRI data revealed an association between sAA levels and left thalamic activity during the first half of the experiment that disappeared during the second half. No significant correlation between cortisol and thalamic activity was observed. Results indicate that an fMRI experiment may elicit subjective and neuroendocrine stress reactions that can influence functional activation patterns.

Post-traumatic stress disorder (PTSD) is a psychiatric condition caused by exposure to a traumatic event. Veterans are at especially high risk of PTSD. In Canada, in a survey conducted in 2016, 16% of Regular Force Veterans released during 1998-2015 reported having PTSD, which is at least two times higher than the estimated prevalence rate in the general population. Individuals with PTSD experience a range of debilitating symptoms, such as the intrusion of unwanted and distressing memories, persistent flashbacks, hypervigilance and nightmares. The neuropathophysiological mechanisms underlying symptoms of PTSD are not well understood, which remains a significant barrier to developing effective treatments. Hallmark PTSD symptoms such as hyperarousal and sleep disturbances may be related to dysregulation of noradrenaline (NA), a neurotransmitter produced in the locus coeruleus (LC) known to modulate cognition, arousal and sleep. This thesis examines the possible associations between dysregulation in rapid-eye-movement (REM) sleep and dysfunction in NA-containing neurons in the LC among veterans with PTSD. Twenty-two operationally deployed veterans with a history of PTSD were recruited through the Royal Ottawa Mental Health Centre in Ontario, Canada. A novel, non-invasive neuroimaging method, neuromelanin-sensitive magnetic resonance imaging (NM-MRI), was used to detect a by-product of NA called neuromelanin (NM) in the LC of each participant. Then a contrast-to-noise ratio (CNR) was calculated to obtain a marker of the NA function. The LC was segmented into three subdivisions to assess whether the association between NM and REM sleep may differ across regions of the LC. As hypothesized, we observed different associations between NM and REM sleep across regions of the LC. After controlling for antidepressant usage, there was (i) a moderate, negative, significant correlation between the percentage of REM sleep and rostral LCCNR, r(19) = -.476, p = .029, (ii) a weak positive non-significant correlation between the percentage of REM sleep and caudal LCCNR, r(19) = .33, p = .145, and (iii) no significant correlation between REM sleep percentage and LCCNR in the middle LC, r(19) = -.04, p = .876. This thesis is the first study to show that NM and REM sleep may be related in veterans with PTSD and that this relationship may vary across subdivisions of the LC. These results improve understanding of REM sleep among individuals with PTSD. The results may stimulate the investigation of novel pharmacotherapy focused on sleep disturbances in PTSD, the development of personalized treatments for PTSD, and the search for clinical biomarkers of PTSD based on brain function. The current study also made methodological contributions that may be applicable beyond the research on PTSD to the field of REM sleep and the NA system. Specifically, the current study showed the suitability of the NM-MRI method for examining the connections between NM and REM sleep, and it showed that segmenting the LC can lead to a more nuanced understanding of its role in the human body.

Catechol-O-methyltransferase (COMT) metabolises catechol-containing compounds, including dopamine. The aim of this thesis was to investigate whether COMT is involved in hippocampal function. This thesis also explored the role of functional polymorphisms within the COMT gene in the pathogenesis of schizophrenia and schizophrenia-related phenotypes. First, as part of a study investigating the role of COMT in schizophrenia, human hippocampal COMT mRNA levels were shown to be neither altered in schizophrenia or bipolar disease, nor affected by COMT genotype. Hence, functional COMT polymorphisms do not appear to operate by altering gross COMT mRNA expression. Importantly, this study showed that COMT is expressed in the human hippocampus. Second, the role of COMT in hippocampal neurochemistry was explored by studying the effect of pharmacological COMT inhibition on catecholamines and metabolites in rat hippocampal homogenates, and extracellularly, using microdialysis. Both demonstrated that COMT modulates hippocampal dopamine metabolism. Thus, hippocampal COMT is of functional significance with respect to dopamine. Third, the effect of COMT inhibition on hippocampus-dependent behaviour was investigated. The results suggested a memory-enhancing effect of pharmacological COMT inhibition on hippocampus-dependent associative and non-associative forms of short-term memory in rats. In contrast, acute COMT inhibition appeared to have no effect on behavioural correlates of ventral hippocampal function i.e. anxiety-like behaviour. In summary, the expression of COMT mRNA in the human hippocampus, as well as the effect of COMT inhibition on rat hippocampal neurochemistry and hippocampus-dependent behaviour provide evidence for a functional role of COMT in the hippocampus. Moreover, changes in COMT activity alter hippocampal dopamine metabolism, which could be a potential mechanism for the role of COMT in hippocampus-dependent short-term memory.

Depuis les années 60, la maladie de Parkinson est considérée comme une conséquence de la perte des neurones dopaminergiques de la substance noire pars compacta. Cependant, dans les modèles animaux de cette pathologie, la perte dopaminergique seule ne reproduit pas de façon simultanée les symptômes moteurs et non moteurs observés chez les patients. De plus en plus d’études suggèrent l’implication des systèmes noradrénergique et sérotoninergique à la fois dans la manifestation des symptômes mais aussi dans les effets secondaires de la L-Dopa et de la stimulation à haute fréquence (SHF) du noyau sous thalamique (NST). Le travail de cette thèse s’inscrit dans ce champ de recherche visant une meilleure compréhension de la physiopathologie et la thérapie de la maladie de Parkinson.Dans un premier temps, nous nous sommes intéressés au rôle respectif des trois monoamines dans la manifestation des symptômes moteurs et non moteurs ainsi que dans l’activité pathologique de trois structures majeures des ganglions de la base, le NST, la pars reticulata de la substance noire et le globus pallidus. L’ensemble de nos résultats démontre que la perturbation des trois systèmes monoaminergiques joue un rôle important à la fois dans la manifestation des troubles moteurs et non moteurs mais aussi dans l’induction de l’activité électrique pathologique des neurones au sein des ganglions de la base. Dans un second temps, nous avons étudié l’efficacité des traitements antiparkinsoniens sur les troubles moteurs et non-moteurs induits par les différentes déplétions monoaminergiques. Nos résultats montrent que quand la déplétion dopaminergique est associée à la déplétion d’une autre monoamine la SHF du NST présente une efficacité moins importante que celle lors d’une déplétion en dopamine seule. Ceci permet d’expliquer le manque d’efficacité de ce traitement chez certains patients.Enfin, comme peu d’études se sont intéressées au rôle de la noradrénaline dans la modulation de l’activité neuronale au sein des ganglions de la base, nous avons étudié les effets d’agents noradrénergiques injectés localement dans le NST sur le comportement moteur et sur l’activité électrique des neurones du NST. Nos résultats montrent que la modulation noradrénergique au niveau du NST ne dépendait pas de l’innervation dopaminergique au sein des ganglions de la base. De plus, nous avons pu mettre en évidence que les récepteurs alpha1 modulent la fréquence de décharge, tandis que les récepteurs alpha2 jouent un rôle important dans la genèse de l’activité en bouffée des neurones du NST ce qui pourrait être á l’origine des déficits moteurs.Les résultats des travaux de cette thèse ont donc permis d’apporter de nouvelles évidences sur l’implication des trois systèmes monoaminergiques dans la physiopathologie des symptômes moteurs et non moteurs, dans l’activité pathologique des ganglions de la base ainsi que dans l’efficacité des traitements antiparkinsoniens. De plus, nous avons pu montrer que les récepteurs noradrénergiques alpha sont impliqués dans le contrôle de l’activité des neurones du NST et par conséquent dans le contrôle moteur. / The loss of dopamine (DA) nigro-striatal neurons has been the pathophysiological focus of the devastating conditions of Parkinson’s disease, but depletion of DA alone in animal models has failed to simultaneously elicit both the motor and non-motor deficits of PD. There is growing evidence that additional loss of locus coeruleus noradrenaline (NA) and dorsal raphe serotonin (5-HT) neurons in PD could be involved in the clinical expression of many of the observed deficits but also on the efficiency and on the side effects of antiparkinsonian treatments, L-Dopa and High Frequency Stimulation (HFS) of the subthalamic nucleus (STN).First, we focused on the respective role of DA, NA and 5-HT systems on motor and non-motor deficits and on the pathological activity of three basal ganglia nuclei, STN, substantia nigra pars reticulata and globus pallidus. Results of the present study bring new insights into the combined roles of the three monoaminergic systems in the motor and non motor symptoms of PD and also into the pathological activity of basal ganglia nuclei.Second, we studied the involvement of DA, NA and 5-HT depletions on the efficiency of L-Dopa and HFS of STN. Our results show that when DA depletion is combined with another monoamine depletion, STN HFS is less efficient compared to the situation when DA is depleted alone. These data provide a clear explanation on the lack of efficacy of this treatment in some operated parkinsonian patients.Finally, as few studies focused on NAergic modulation of basal ganglia, we studied the effects of NAergic agents locally injected into the STN on motor behavior and also on STN neuronal activity. We show that alpha 1 NAergic receptors are implicated in the modulation of firing rate and that alpha 2 receptors play an important role in the emergence of burst activity, which could be at the origin of motor deficits.Results of this thesis provide new evidences on the involvement of the three monoaminergic systems in motor and non motor symptoms and also in the efficiency of antiparkinsonian treatments. Moreover, we show that NAergic alpha receptors are implicated in the control of STN neuronal activity and consequently in the motor control.

No description available.

Choisir entre l'action ou l'inaction est peut-être le type de décision le plus critique auquel un animal peut faire face. Une formalisation simple de ces choix consiste à évaluer les bénéfices attendus (nourriture, argent par exemple) ainsi que les coûts (punitions, pertes de temps ou d'argent) associés à chaque action et d'optimiser le rapport entre récompenses reçues et coûts assumés. Notre motivation à s'engager dans une action donnée dépend donc de la valeur de ce rapport. Dans le domaine de l'économie comportementale, l’optimisation de ce rapport bénéfices/coûts constitue le principe fondamental qui régule et explique le comportement des individus. Dans mes travaux de thèse, j'ai réalisé une implémentation de ces concepts venant de l'économie comportementale en utilisant une forme expérimentalement quantifiable de coûts: l'effort physique. Dans notre vie de tous les jours, si l'on nous demande de choisir entre deux options rapportant les même bénéfices mais demandant différents efforts (par exemple, travailler 3 ou 7 jours par semaine pour le même salaire), nous choisissons habituellement l'option qui nécessite la plus petite dépense d'énergie, en optant donc pour le moindre effort. Néanmoins, l'effort physique a été beaucoup moins étudié en comparaison à d'autres formes de coûts comme le fait de différer la récompense ou d'en augmenter l'incertitude. Le présent travail de recherche a donc pour but de mettre en lumière les bases neurales de la balance récompense / effort dans la prise de décision. Comprendre comment l'effort affecte la dévaluation des potentielles récompenses a un intérêt particulier pour la prise de décisions économiques mais aussi pour la clinique, étant donné que la diminution de la capacité à accepter d'avoir à exercer un effort est un symptôme-clé de nombreuses pathologies comme l'apathie ou la dépression. Nous faisons l’hypothèse que de tels désordres pourraient résulter de deux différents processus comportementaux: (a) une diminution de la sensibilité aux bénéfices futurs et/ou (b) une sensibilité excessive aux coûts potentiels. Ainsi, lorsqu'interrogés sur les raisons pour lesquelles ils ne veulent pas aller au cinéma regarder un film qu'ils apprécient, les patients apathiques peuvent déclarer que (a) le film n'est pas assez bon (soit une plus faible réponse à la valeur attendue), (b) le cinéma est trop loin (soit une plus forte sensibilité à l'effort anticipé). Afin de tester ces hypothèses, nous avons enregistré l'activité de neurones chez le singe pendant des tâches comportementales. Nous avons trouvé que d'une part, la dopamine encode la valeur de l'action future et oriente le comportement vers l'option demandant le moindre effort. D'autre part, la noradrénaline permet à l'individu de faire face à l'effort à venir en réduisant la sensibilité à l'anticipation de l'effort. En utilisant une approche pharmacologique, nous avons démontré que lorsque le niveau de noradrénaline est augmenté, les singes exercent d'avantage d'effort. En outre, nous avons montré que les potentiels locaux de champ dans le cortex pré-frontal ventro-médian, enregistrés dans une tâche comportementale identique, sont modulés par la valeur attendue et prédisent le choix du singe. En résumé, ce travail permet de départager en partie les circuits neuronaux impliqués dans le calcul de la balance récompense / effort, principalement encodée par les neurones dopaminergiques et dans les potentiels locaux de champ au niveau du cortex pré-frontal ventro-médian. Enfin, ce travail souligne le rôle de la noradrénaline dans la mobilisation de l'énergie d'un individu afin de faire face au défi que représente l'effort physique. / There is perhaps no more critical factor for the behaviour of an animal than the way it chooses between action and inaction. A simple way to formalise such choices is to evaluate the predicted benefit (e.g. food, money) and costs (e.g. punishments, losses, delays) associated with each action and optimise the rates at which rewards are received and costs avoided. Our motivation to perform a given action depends upon such value ratio. In the current behavioural economics literature, the optimisation of the benefits/costs ratio stands as the fundamental principle that regulates and explains agents’ behaviour. In my Ph.D. studies, I implement a realistic model of such concepts from behavioural economics by using an empirical type of cost: physical effort. In our everyday life, if we are asked to choose between two options that imply the same reward but different efforts (e.g., working 3 or 7 days per week for the same salary), we usually opt for the alternative that requires the slightest energy expenditure, thus the least effort. However, physical effort has been far less studied compared to other decision costs such as delay or uncertainty. The present Ph.D. work aims at highlighting the neuronal bases of such reward/effort tradeoff. Understanding how effort cost affects the discounting of potential rewards has a clear significance for economic decisions and clinics, since the reduced willingness to exert effort is a key signature of several clinical disorders such as apathy and depression We suggest that disorders such as apathy could result from two different behavioural processes: (a) a decreased responsiveness to future benefits and/or (b) an excessive sensitivity to potential costs. For instance, when asked why they would not go see a movie they like, patients may say that (a) the movie is not good enough (i.e. low responsiveness to expected value) or that (b) the theatre is too far away (i.e. high sensitivity to anticipated effort). To test our hypothesis, we combined behavioural tasks and pharmacological approach with neuron recordings in monkeys, targeting specifically two majors actors of the rewarding and effort system, dopamine and noradrenaline. We found that dopamine and noradrenaline have distinct but complementary roles. On the one hand, dopamine tracks the reward value of future outcomes and orient the behaviour towards the least effortful options. On the other hand, noradrenaline enables subjects to face the effort at hand, reducing the sensitivity to anticipated effort. Using a pharmacological approach, we found that, when we increase noradrenaline, monkeys exerted significantly more effort. Moreover, we have found that local field potentials in the ventromedial prefrontal cortex recorded in the same task encode the expected value and predict action selection. In summary, this Ph.D. work allows to disentangle some of the neuronal circuits implicated in the computation of the reward/effort tradeoff, mainly encoded by dopaminergic neurons and in the local field potential of the ventromedial prefrontal cortex. On the other hand, this work highlights the role of noradrenaline in the energization of behaviour to face the challenge represented by the physical effort.

Background: Medication-related interferences with measurements of catecholamines and their metabolites represent important causes of false-positive results during diagnosis of phaeochromocytomas and paragangliomas (PPGLs). Such interferences are less troublesome with measurements by liquid chromatography with tandem mass-spectrometry (LC-MS/MS) than by other methods, but can still present problems for some drugs. Levodopa, the precursor for dopamine used in the treatment of Parkinson’s disease, represents one potentially interfering medication. Methods: Plasma and urine samples, obtained from 20 Parkinsonian patients receiving levodopa, were analysed for concentrations of catecholamines and their O-methylated metabolites by LC-MS/MS. Results were compared with those from a group of 120 age-matched subjects and 18 patients with PPGLs. Results: Plasma and urinary free and deconjugated (freeþconjugated) methoxytyramine, as well as urinary dopamine, showed 22- to 148-fold higher (P<0.0001) concentrations in patients receiving levodopa than in the reference group. In contrast, plasma normetanephrine, urinary noradrenaline and urinary free and deconjugated normetanephrine concentrations were unaffected. Plasma free metanephrine, urinary adrenaline and urinary free and deconjugated metanephrine all showed higher (P<0.05) concentrations in Parkinsonian patients than the reference group, but this was only a problem for adrenaline. Similar to normetanephrine, plasma and urinary metanephrine remained below the 97.5 percentiles of the reference group in almost all Parkinsonian patients. Conclusions: These data establish that although levodopa treatment confounds identification of PPGLs that produce dopamine, the therapy is not a problem for use of LC-MS/MS measurements of plasma and urinary normetanephrine and metanephrine to diagnose more commonly encountered PPGLs that produce noradrenaline or adrenaline.

Los receptores &#946;-adrenérgicos (&#946;AR) y de serotonina (5-HT4) median sus efectos en tejidos cardiacos a través de la ruta receptor-Gs-AC-AMPc. Las fosfodiesterasas (PDE) son una amplia familia de enzimas cuya función es la degradación del AMPc. Se desconocía que isoenzimas de PDEs son responsables de la hidrólisis de AMPc en las diferentes regiones cardiacas. El objetivo de esta tesis doctoral es investigar que isoenzimas de PDEs tienen actividad en el miocardio humano, porcino y de roedores. Se han realizado estudios cronotrópicos, inotrópicos, lusitrópicos, bioquímicos y electrofisiológicos. Los principales resultados son: Las PDEs se comportan de manera distinta en las diferentes regiones cardiacas y compartimentos celulares; y La frecuencia basal de nódulo sinusal está controlada por PDEs pero en ninguna especie estudiada las PDEs controlan la taquicardia causada por los &#946;ARs y los receptores 5-HT4. La extrapolación de la función de las PDEs al humano debe h acerse con cautela. / Myocardial &#946;-adrenoceptors (&#946;AR) and serotonin receptors (5-HT4) mediate their signals through the receptor-Gs-AC-cAMP pathway. Phosphodiesterases (PDEs) are a large enzyme family that degrade cAMP. It was unknown which PDE isoenzymes are responsible for the hydrolysis of the cAMP in different cardiac regions. The aim of this doctoral thesis is to investigate which isoenzymes have a role in human, porcine and rodent myocardium. We performed chronotropic, inotropic, lusitropic, biochemical and electrophysiological studies. The key results are: PDEs have different roles in different cardiac regions and cellular compartments; and the basal beating rate of the sinoatrial node is controlled by PDE3 and/or PDE4, but these PDEs do not limit the tachycardia mediated through the stimulation of &#946;1AR, &#946;2AR and 5-HT4. Given the diverse roles of PDE3 and PDE4 and their dependence on species, extrapolation to humans should be done cautiously because these animal models usually do not reflect the human myocardium.

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.